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We investigated sex‑related differences in the prognosis of patients with hypertrophic 
cardiomyopathy (HCM) using the Korea National Health Insurance Service database. From 2010 
to 2016, 9524 patients diagnosed with HCM and had more than 1‑year follow‑up period were 
analyzed. The primary endpoint was the composite of cardiovascular death or new‑onset heart 
failure (HF) admission. Propensity score‑matching analysis was performed to adjust for different 
baseline characteristics. With a 4.4‑years’ median follow‑up interval (range 2.0–6.6 years) and male 
predominance (77.6%), women with HCM were older (52.6 ± 9.7 vs. 51.4 ± 9.1, p < 0.001), had lower 
incomes, more comorbidities based on Charlson comorbidity index. Women with HCM had a higher 
incidence of the primary endpoint than men (incidence rate: 34.15 vs. 22.83 per 1000 person‑years, 
log‑rank p < 0.001). Multivariable Cox analysis showed that female sex was a poor prognostic factor 
for the primary endpoint (HR 1.43, 95% CI 1.24–1.64, p < 0.001). This was mainly driven by a higher 
incidence of new‑onset HF admission (HR 1.55, 95% CI 1.34–1.80). However, there was no difference in 
the incidence of cardiovascular death between the sexes. This result was concordant in the propensity 
score‑matched cohort. In conclusion, women with HCM have worse prognosis, which was mainly 
driven by a higher new‑onset HF admission.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease that is transmitted in an autosomal dominant 
fashion with extreme diversity in clinical presentation and natural  history1,2. Despite an autosomal dominant 
transmission, earlier investigations of the disease frequently reported male predominance in  prevalence3–7, sug-
gesting sex differences in clinical expression. Although prognostic differences according to sex in a variety of 
acquired cardiac diseases including coronary artery disease, atrial fibrillation, valvular heart disease, and aortic 
diseases have been  reported8–12, there have been conflicting results regarding sex differences in the prognosis 
of  HCM6,7,13–15. Given the improved prognosis of HCM patients in the contemporary management era, a larger 
number of HCM patients may be required to draw more solid conclusion. Differences in the baseline characteris-
tics, especially older age in women than men, also made it difficult to draw a definite  conclusion3,5–7,16. Therefore, 
this study was designed to investigate sex differences in the prognosis of HCM by using a large database of the 
Korea National Health Insurance Service (NHIS). In addition, we utilized the propensity score (PS)-matching 
analysis to balance the differences in the baseline characteristics of both sexes.
Results
Baseline characteristics of the study subjects. A total of 9524 patients were finally included in this 
study (mean age 51.7 ± 9.3 years); the study population was predominantly male (77.6%, n = 7388). The baseline 
clinical characteristics of the patients are summarized in Table 1. Generally, Women were one year older than 
men (52.6 ± 9.7 vs. 51.4 ± 9.1, p < 0.001) and had a higher Charlson comorbidity index (CCI) (2.31 ± 1.98 vs. 
1.95 ± 1.89, p < 0.001), but were less likely to have a history of chronic kidney disease, ischemic heart disease 
(IHD) requiring coronary intervention, and myocardial infarction.
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Clinical outcomes in the original cohort. The median follow-up duration was 4.4 (interquartile range 
[IQR] 2.0–6.6) years or 39,267 patient-years (4.4 [IQR 1.9–6.1] years for women; 4.5 [IQR 2.1–6.7] years for 
men). During follow-up, the primary endpoint was reached in 956 (10.0%) patients; cardiovascular death in 227 
(2.4%) patients, and new-onset heart failure (HF) admission in 804 (8.4%) patients. Seventy-five patients expe-
rienced both new-onset HF admission and cardiovascular death events, for whom the first event, i.e., new-onset 
HF admission, was included in the primary endpoint analysis. All-cause death was observed in 379 patients 
(4.0%).
According to the Kaplan–Meier survival curves (Fig. 1), women had a higher incidence of new-onset HF 
admission than men (p < 0.001), whereas the incidences of cardiovascular death in women and men were similar 
(p = 0.265). Therefore, the significantly higher occurrence of the primary endpoint in women was mainly driven 
by a greater number of new-onset HF admission (34.15 vs. 22.83 per 1000 person-years for women and men, 
respectively, p < 0.001) (Table 2). There was no difference between the sexes regarding all-cause death (p = 0.546) 
(Fig. 1D).
Univariate Cox analysis revealed significant differences in baseline characteristics between men and women, 
including sex, age, CCI, income, hypertension, dyslipidemia, chronic kidney disease, IHD requiring coronary 
intervention, atrial fibrillation, and use of beta-blocker (Supplementary Table 1). Multivariate Cox regression 
analysis conducted after adjusting for the clinical differences in the univariate Cox analysis showed that the female 
sex remained a significant poor prognosticator for predicting the primary endpoint in two different multivariable 
models of the original cohort. Of note, this finding was mainly driven by the significantly higher incidence of 
new-onset HF admission among women with HCM, and there was no statistical difference in the incidences of 
cardiovascular death or all-cause death in two different multivariable models (Table 3).
Clinical outcomes in the propensity score‑matched cohort. In the original HCM cohort, baseline 
clinical characteristics were significantly different between women and men (Table 1). Thus, to balance the base-
line clinical characteristics of both sexes, we created a PS-matched HCM cohort. After PS-matching, each base-
line clinical characteristic was well balanced (Supplementary Table 2).
In the PS-matched cohort, the rate of occurrence of the primary endpoint was also higher among women 
than among men (32.06 vs. 22.24 per 1,000 person-years, log-rank p < 0.001) (Fig. 2 and Supplementary Fig. 1A). 
The clinical outcomes of cardiovascular death, new-onset HF admission, and all-cause death were all consist-
ent with those in the original cohort (Supplementary Fig. 1B–D). In the PS-matched cohort, multivariable Cox 
regression analysis showed that female sex remained a significant poor prognosticator for the primary endpoint 
(hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.22–1.68; p < 0.001), a finding that was again driven by the 
higher incidence of new-onset HF admission among women (HR 1.54, 95% CI 1.30–1.82; p < 0.001) (Table 3).
Sensitivity analysis of patients without hypertension. To eliminate the potential confounding 
effects of hypertension on increased ventricular wall thickness, we performed a sensitivity analysis for 5568 
patients without the International Classification of Disease, Tenth Revision (ICD-10) code of hypertension in the 
Table 1.  Baseline characteristics in the original cohort of patients with HCM. HCM hypertrophic 
cardiomyopathy, IHD ischemic heart disease, RAS renin–angiotensin system.
Total (N = 9524) Men (N = 7388) Women (N = 2136) p
Age 51.7 ± 9.3 51.4 ± 9.1 52.6 ± 9.7 < 0.001
Income, low 20% 1616 (17.0) 1133 (15.3) 483 (22.6) < 0.001
Underlying disease, n (%)
Hypertension 3956 (41.5) 3089 (41.8) 867 (40.6) 0.313
Diabetes mellitus 890 (9.3) 703 (9.5) 187 (8.8) 0.287
Dyslipidemia 2346 (24.6) 1819 (24.6) 527 (24.7) 0.961
IHD requiring coronary intervention 94 (1.0) 82 (1.1) 12 (0.6) 0.024
Myocardial infarction 243 (2.6) 203 (2.8) 40 (1.9) 0.024
Atrial fibrillation 612 (6.4) 479 (6.5) 133 (6.2) 0.670
Previous stroke 420 (4.4) 323 (4.4) 97 (4.5) 0.737
Chronic kidney disease 234 (2.5) 195 (2.6) 39 (1.8) 0.032
End-stage renal disease 63 (0.7) 51 (0.7) 12 (0.6) 0.519
Medication, n (%)
RAS blocker 2934 (30.8) 2307 (31.2) 627 (29.4) 0.099
Beta-blocker 3387 (35.6) 2628 (35.6) 759 (35.5) 0.975
Calcium channel blocker 1393 (14.6) 1087 (14.7) 306 (14.3) 0.656
Antiplatelet agent 2783 (29.2) 2188 (29.6) 595 (27.9) 0.115
Statin 2334 (24.5) 1803 (24.4) 531 (24.9) 0.667
Charlson comorbidity index 2.03 ± 1.92 1.95 ± 1.89 2.31 ± 1.98 < 0.001
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Figure 1.  Kaplan–Meier curve of the cumulative incidence of clinical events in the original cohort of patients 
with hypertrophic cardiomyopathy. (A) The primary endpoint of cardiovascular death or new-onset HF 
admission; (B) cardiovascular death; (C) new-onset HF admission; (D) all-cause death. CV cardiovascular, HF 
heart failure.
Table 2.  Clinical outcome in the original cohort of patients with HCM. HCM hypertrophic cardiomyopathy, 
HF heart failure.
Numbers Events Incidence rate (per 1000) p
Primary endpoint 9524 956 25.36 < 0.001
Men 7388 668 22.83
Women 2136 288 34.15
Cardiovascular death 9524 227 5.78 0.265
Men 7388 167 5.52
Women 2136 60 6.67
New-onset HF admission 9524 804 21.33 < 0.001
Men 7388 547 18.69
Women 2136 257 30.47
All-cause death 9524 379 9.65 0.546
Men 7388 297 9.81
Women 2136 82 9.12
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original cohort. Baseline characteristics of the patients without hypertension were basically the same as those of 
the patients in the original cohort (Supplementary Table 3).
Sensitivity analyses of the numbers of events for each endpoint in this cohort are presented in Supplementary 
Table 4. Specifically, women showed a significantly higher incidence of the primary endpoint after multivariable 
Cox regression analysis, which was adjusted for age, CCI, income, and clinical variables including dyslipidemia, 
IHD requiring coronary intervention, chronic kidney disease, atrial fibrillation, and use of beta-blocker (HR 
1.52, 95% CI 1.27–1.82; p < 0.001). This finding was also mainly influenced by the significantly higher incidence 
of new-onset HF admission (HR 1.66, 95% CI 1.37–2.01; p < 0.001). There was no significant difference in the 
incidences of cardiovascular death for both sexes (HR 1.31, 95% CI 0.90–1.89; p = 0.154). The incidence of all-
cause death for women and men were also similar (p = 0.579).
Discussion
We here investigated the sex-related differences in the prognosis of patients with HCM. To the best of our knowl-
edge, we have included the largest ever number of patients with HCM with the aim of evaluating the sex-related 
differences in their prognosis. In this study, women with HCM were generally older, had more comorbidities, 
and lower socioeconomic status, but were less likely to have IHD requiring coronary intervention and a history 
of myocardial infarction or chronic kidney disease than men with HCM. In the original cohort, the PS-matched 
cohort, and the patients without hypertension cohort (i.e., the cohort for sensitivity analysis), women with 
HCM consistently had poorer prognosis for the primary endpoint than men. This outcome was mainly due to a 
higher incidence of new-onset HF admission among women. However, there was no difference in the incidence 
of cardiovascular or all-cause death between the sexes.
For the last two decades, several studies were conducted on patients from different groups and of different 
ethnicities to determine whether women with HCM have poorer prognosis than men with  HCM3,6,7,13,15,17–20. In 
Table 3.  Sex differences in the multivariable Cox regression analysis in the original and the propensity score-
matched cohorts of patients with HCM. HCM hypertrophic cardiomyopathy, HR hazard ratio, HF heart failure. 
a Multivariate clinical model 1 was adjusted for age and Charlson comorbidity index. b Model 2 was adjusted for 
age, Charlson comorbidity index, low income, hypertension, dyslipidemia, ischemic heart disease requiring 
coronary intervention, chronic kidney disease, atrial fibrillation, and beta-blocker.
Variables
Unadjusted Model  1a Model  2b Propensity score-matched
HR for women (95% CI) p HR for women (95% CI) p HR for women (95% CI) p HR for women (95% CI) p
Primary endpoint 1.49 (1.30–1.71) < 0.001 1.39 (1.21–1.60) < 0.001 1.43 (1.24–1.64) < 0.001 1.43 (1.22–1.68) < 0.001
Cardiovascular death 1.18 (0.88–1.59) 0.266 1.07 (0.80–1.44) 0.645 1.11 (0.83–1.50) 0.478 1.27 (0.91–1.78) 0.162
New-onset HF admission 1.63 (1.41–1.89) < 0.001 1.53 (1.31–1.77) < 0.001 1.55 (1.34–1.80) < 0.001 1.54 (1.30–1.82) < 0.001
All-cause death 0.93 (0.73–1.18) 0.546 0.82 (0.64–1.05) 0.118 0.83 (0.65–1.07) 0.144 0.91 (0.69–1.21) 0.525
Figure 2.  Kaplan–Meier curve of the cumulative incidence of the primary endpoint in the original and 
propensity score-matched cohort of patients with hypertrophic cardiomyopathy. The rate of occurrence of 
the primary endpoint, a composite of cardiovascular death or new-onset heart failure, was higher among 
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a recent study by Geske et al., which had a large sample size and the longest follow-up duration so far, women 
with HCM had a significantly higher incidence of all-cause mortality than both men with HCM and the general 
 population6. However, two other large studies by Olivotto et al. and Rowin et al. did not show any difference in 
survival rate between the sexes; the mean ages of the patients in the latter two studies were lower than that in the 
study by Geske et al. (mean age 42 and 46 years vs. 55)3,6,7. Our study’s mean age of the patients was 51, which may 
explain the insignificant difference in survival rate between the sexes. There are some plausible reasons why there 
was no sex-related difference in mortality rates. First, we focused on the association of sex with clinical course 
and survival in HCM. The age of patients in the original cohort was slightly younger, and thus the incidence of 
cardiovascular or all-cause death was so lower than that of the elderly general population that there may be no 
statistical difference between the two groups. Second, although the incidence of HF was higher among women, 
the incidence of HF-related death, one of the main causes of HCM-related death, might have decreased  recently7. 
In a previous study of the HCM population in Korea, the proportion of implantable cardioverter defibrillator 
(ICD) implanted for primary prevention purposes was similar to that of large HCM cohorts of other countries 
(2.9% each)7,21. Since the number of patients with HCM in our study was greater than those of other previous 
studies, we could more actively adjust for the older age of women with HCM or referral bias using several sta-
tistical methods. Nevertheless, a well-designed prospective cohort study of patients of different ethnicities will 
be needed to determine the association of sex with the prognosis of HCM patients.
As reported in previous studies, our data showed a higher incidence of new-onset HF admission among 
women with HCM than among  men7,22. One of the possible reasons for this might be the differences in cardiac 
chamber sizes between sexes. Investigations conducted using transthoracic  echocardiography23 and cardiac 
magnetic resonance imaging before and after correction for body surface area showed that both women in the 
healthy  population24,25 and HCM mutation  carriers20 have smaller left ventricular (LV) end-diastolic dimensions 
and volumes than men. Nevertheless, there is no sex-related difference in the diagnostic criterion for HCM, i.e., 
a maximal LV wall thickness of at least 15 mm (or 13 mm in first-degree relatives)26. If the LV wall thickness of 
women reached a cutoff value enough to elicit a diagnosis of HCM, the LV dimensions and volumes in women 
with HCM would be relatively smaller than that of men. This may be the cause of the higher peak LV outflow 
gradient at initial diagnosis recorded in previous  studies6,7,22 and higher incidence of new-onset HF admission 
in the present study. Second, women have a higher prevalence of HF with preserved ejection fraction (HFpEF) 
than men in the general population due to lower diastolic reserve, more frequent age-associated ventricular-
arterial uncoupling, and smaller vessel  size27,28. This trend was also observed in the HCM cohort; women with 
HCM had higher early mitral inflow velocity/early mitral annular velocity ratio and elevated right ventricular 
systolic pressure, both of which are parameters used for estimating LV filling  pressure6,18. The beneficial effect 
of beta-blocker in patients with HCM was noted in a pre-specified subgroup analysis (Supplementary Fig. 2), 
which may be mediated by decreased inotropy with a decreased LV outflow pressure gradient and reduced heart 
rate with increased time for diastolic  filling6,29. Third, in the present study, a higher proportion of women had 
income below the lowest 20% than men. In a previous study, the socioeconomic status affected the incidence and 
long-term outcomes of patients with  HF30. Another international multicenter study also showed that women 
had higher Gini coefficients, which means more income inequality and can result in worse HF outcomes, even 
though they had fewer comorbidities than  men31. Besides, decreased estrogen levels after menopause can par-
tially explain the possible mechanisms underlying the poor HF outcomes in women with HCM. Specifically, LV 
mass in female mice with LV hypertrophy has been reported to increase after  ovariectomy32. In another animal 
study, estrogen compounds had a proapoptotic effect and were not protective in the setting of  HCM33. Although 
the lack of echocardiographic and biological data in the NHIS database makes it difficult to demonstrate the 
mechanisms underlying the poor HF outcome among the women with HCM in the present study, our findings 
are concordant with those of the previous  studies7,22. The HR of the largest sample size in the present study also 
had a greater magnitude than those of previous studies after adjustment with several statistical methods.
Our study has some limitations. First, since this was a nationwide cohort study conducted using the NHIS 
database, we could not evaluate the echocardiographic parameters, such as LV peak pressure gradient, or cardiac 
magnetic resonance imaging results of the patients enrolled. This is the inherent limitation of national claims 
data. Additionally, we could not analyze the morphological phenotype of HCM or the prevalence of obstructive 
HCM, either. However, the diagnosis of HCM in Korea is strictly controlled periodically by the NHIS and a 
medical expert from the Health Insurance Review and Assessment Service (HIRA)34. Further, the ICD-10 and 
Rare Intractable Disease (RID) code-based diagnosis of HCM was well-matched with a previous echocardiog-
raphy-based diagnosis of  HCM35. Second, a previous study suggested that women with HCM had a smaller LV 
cavity size than men and that elderly women with HCM had a higher peak LV outflow pressure gradient due to 
gender-dependent contractile force and different structural  remodeling36. Annual trends in number of diagnoses 
and age at diagnosis are both increasing, which seems to be irrespective of geographical or  ethnicity5,37. This 
phenomenon might be due to increased physician awareness, diagnostic sensitivity or unknown mechanism 
related with sex-difference according to age. The present study only enrolled patients aged < 65 years, and thus 
we cannot investigate gender-specific changes in LV systolic function and remodeling pattern with age. However, 
exclusion of older HCM patients may be reasonable because LV wall thickness tends to increase in older age due 
to hidden hypertension or unknown  causes38. We could focus on the association of sex with prognosis in patients 
with HCM by enrolling relatively young patients. Third, the prevalence of hypertension, which complicates a 
strict diagnosis of HCM, looks higher. However, the proportion of patients with hypertension in the present study 
was similar to that in other previous studies of HCM  cohorts6,7. Furthermore, the results in the original cohort 
were concordant with those in the HCM patients without hypertension of the sensitivity analysis.
In conclusion, women with HCM have a higher incidence of the primary endpoint than men with HCM. 
This result was mainly driven by a higher new-onset HF admission in women with no difference in all-cause or 
cardiovascular mortality between women and men.
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Methods
Data source and study population. We conducted this nationwide population-based cohort study 
using the Korean NHIS claims database. The Korean NHIS is a mandatory universal health insurance pro-
gram managed by the Korean government since 1989 and offers comprehensive medical care to 97% of the 
Korean  population39. The remaining 3% of Koreans with evidence of low income are covered by the Medical Aid 
Program; information from this program has been incorporated into a single database since 2006. The NHIS 
database includes detailed information of each registered individual, including data on demographic character-
istics, health behavior, diagnoses, prescriptions, surgeries or procedures, and health care utilization (i.e., hos-
pitalization)39. This database has been previously used in many published studies, and its validity as a reliable 
data source has been  established40–42. Additionally, the HIRA system provides regular evaluation data, quality 
control data, and feedback about the whole medical care system in Korea. Through the cooperation of the NHIS 
and HIRA, a large database of the medical information of all Koreans was established under the strict supervi-
sion of the Ministry of Health and  Welfare34. This database encompasses information on demographics, medi-
cal facility utilization history, diagnoses, prescriptions, and the national health exam results of a given  year43. 
From this database, we selected subjects who were aged ≥ 20 years between January 1, 2010, and December 31, 
2016. To minimize the possibility of hypertrophic changes of the myocardium in older  people38, 8676 patients 
aged > 65 years were excluded. We also excluded 364 patients who had less than a year of follow-up and 524 
patients who had the ICD-10 code of HF in their record at the time of enrollment. A total of 9524 patients with 
HCM were finally included in the study (Fig. 3). This study complied with the provisions of the 2013 Declaration 
of Helsinki. The study was approved by the Institutional Review Board of Seoul National University Hospital 
(E-1092-058-1009), and the need for informed consent was waived by the Institutional Review Board of Seoul 
National University Hospital due to the retrospective nature of the study.
Diagnosis of HCM and its validity. HCM was defined as (1) record of at least one admission or outpa-
tient clinic visit with ICD-10 code of I42.1 or I42.2; and (2) registration in the RID program (code of V127). In 
Korea, HCM falls under the RID category, in which patients are designated as special medical aid beneficiaries 
with expanding benefit of the NHIS. Since 2006, the Korean government has introduced an initiative covering 
90% of all medical expenses claimed by these patients. Therefore, the diagnosis of HCM is strictly determined 
and monitored via thorough verification using clinical and imaging evidences, and periodical reviews by medi-
cal experts and health insurance professionals, according to an act established by the Ministry of Health and 
Welfare. Furthermore, the definition of HCM according to a diagnostic code was validated by our institution 
in a previous study, by reviewing medical records, including echocardiography or cardiac magnetic resonance 
imaging data, and comparing the diagnostic accuracy of the  code35.
Covariates. Previously published detailed methods were adopted for this  study35,44,45. Age and sex data 
were retrieved using resident identification numbers. Income level was dichotomized at the lowest 20% and 
was presented as a categorical variable. The detailed definition of comorbidities, including hypertension, dia-
betes mellitus, dyslipidemia, IHD (requiring stent insertion), myocardial infarction, peripheral artery disease, 
atrial fibrillation, ischemic/bleeding stroke, chronic kidney disease / end-stage renal disease is summarized in 
Supplementary Table 5. CCI was also calculated as previously  described46,47. Prescription lists, including renin–
angiotensin–aldosterone system blocker, beta-blocker, calcium channel blocker, statin, and antiplatelet agent, 
were ascertained.
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Study outcome and follow‑up. The primary endpoint was defined as a composite of cardiovascular 
death and new-onset HF. The secondary endpoint included the individual components of the primary endpoint 
and all-cause death. New-onset HF was defined as a newly acquired I50 diagnostic code on admission after the 
diagnostic code for HCM was established. The study subjects were followed up until the occurrence of each 
endpoint or until December 31, 2017, whichever came first.
Statistical analysis. Descriptive statistics were presented as means ± standard deviations or medians 
(IQRs) for continuous variables and numbers (percentages) for categorical variables. For the comparison 
between groups, the unpaired Student’s t-test was applied for continuous variables, and the χ2 test or Fisher’s 
exact test was used for categorical variables, as appropriate. The incidence rates of death or new-onset HF events 
were calculated by dividing the number of detected cases by the follow-up duration, and were presented as a 
value per 1000 person-years. Kaplan–Meier curves were used to present the cumulative incidence of the primary 
and secondary endpoints by using a log-rank test for statistical analysis. Multivariable Cox proportional-hazards 
analysis with two nested models were used to identify the independent risk factors for the primary and second-
ary endpoints, which were expressed as HRs and corresponding 95% CIs. The variables with a p-value of < 0.10 
for the primary endpoint in the univariable Cox analysis were selected and included in the multivariable Cox 
analysis.
To adjust for the imbalance between the baseline characteristics of men and women, we used two different 
approaches. First, the multivariable Cox regression analysis was performed while adjusting for the baseline 
characteristics that were significantly different in the univariable analysis. Second, the PS-matching analysis 
was adopted to balance the differences in covariates. It was performed with a 3:1 greedy matching technique. 
We set a caliper for nearest-neighbor matching within the first four to eight digits. For sensitivity analysis, we 
excluded 3,956 patients with ICD-10 codes indicating hypertension (I10-13, I15) in their records and repeated 
the statistical analyses.
All statistical analyses were executed using the SAS software, Version 9.4 of SAS System for Windows, Copy-
right 2021 (SAS Institute Inc., Cary, NC), and R version 3.6.0 software (R Development Core Team, Vienna, 
Austria). A two-sided p-value of < 0.05 was considered a significant difference.
Data availability
The data is unavailable outside NHIS system.
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